Articles
  • Review|Open Access

    Aberrant pre-mRNA splicing regulation in the development of hepatocellular carcinoma

    Supriya Sen
    Alternative splicing is a highly regulated process that plays a critical role in diversification of the transcriptome and proteome in the cell. Several diseases, including different types of cancers, have been associated with aberrant regulation of alternative splicing. Thus, correcting... Read more
    Hepatoma Res 2018;4:37. | doi:10.20517/2394-5079.2018.39
    Published on: 18 Jul 2018  | Viewed:0  | Downloaded:0
    +HTML| PDF
  • Review|Open Access

    Hepatitis C related hepatocellular carcinoma in the era of direct-acting antivirals

    Akshata Moghe , Obaid S. Shaikh
    Globally, hepatocellular carcinoma (HCC) is the second leading cause of cancer related death. Hepatitis C virus infected patients with cirrhosis or bridging fibrosis are particularly at risk. The risk is reduced among patients who achieve viral clearance with interferon-based regimens.... Read more
    Hepatoma Res 2018;4:36. | doi:10.20517/2394-5079.2018.54
    Published on: 18 Jul 2018  | Viewed:0  | Downloaded:0
    +HTML| PDF
  • Original Article|Open Access

    [18F]FDG PET imaging evaluation on non-alcoholic fatty liver disease and hepatocellular carcinoma model treated with sorafenib

    Fernando Gomes de Barros Costa , José Tadeu Stefano , Daniele de Paula Faria , Caio de Souza Levy , Maria Cristina Chammas , Camila de Godoi Carneiro , Isabel Veloso Alves Pereira , Bruno Cogliati , Flair José Carrilho , Claudia P. Oliveira
    Aim: Evaluate the effect of sorafenib in a rat model of non-alcoholic fatty liver disease (NAFLD) related to hepatocellular carcinoma (HCC) by quantifying the correlation between changes in glucose metabolism on PET imaging and degree of tumor differentiation. Methods: NAFLD related HCC was... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:35. | doi:10.20517/2394-5079.2018.06
    Published on: 12 Jul 2018  | Viewed:102  | Downloaded:1
    +HTML| PDF
  • Review|Open Access

    Somatostatin in hepatocellular carcinoma: experimental and therapeutic implications

    Elias Kouroumalis , Demetrius Samonakis , George Notas
    The neuropeptide somatostatin has been shown to control the secretion of several hormones and growth factors, but also to inhibit the proliferation of several tumor cells. Hepatocellular carcinoma (HCC) is a leading cause of death all over the world due to very limited treatment modalities. Early... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:34. | doi:10.20517/2394-5079.2018.33
    Published on: 11 Jul 2018  | Viewed:49  | Downloaded:3
    +HTML| PDF
  • Review|Open Access

    Living donor liver transplantation for patients with hepatocellular carcinoma in Japan

    Yasuhiko Sugawara , Hidekazu Yamamoto , Taizo Hibi
    Liver transplantation has now been an established treatment for hepatocellular carcinoma and cirrhosis. The Milan criteria have been accepted and applied widely in the world as an indication for deceased donor liver transplant. Due to the severe organ shortage, however, living donor liver... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:33. | doi:10.20517/2394-5079.2018.69
    Published on: 10 Jul 2018  | Viewed:121  | Downloaded:4
    +HTML| PDF
  • Review|Open Access

    The multifaceted oncogene SND1 in cancer: focus on hepatocellular carcinoma

    Saranya Chidambaranathan-Reghupaty , Rachel Mendoza , Paul B. Fisher , Devanand Sarkar
    Staphylococcal nuclease and tudor domain containing 1 (SND1) is a protein that regulates a complex array of functions. It controls gene expression through transcriptional activation, mRNA degradation, mRNA stabilization, ubiquitination and alternative splicing. More than two decades of research... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:32. | doi:10.20517/2394-5079.2018.34
    Published on: 10 Jul 2018  | Viewed:114  | Downloaded:4
    +HTML| PDF
  • Review|Open Access

    Performance of different biomarkers for the management of hepatocellular carcinoma

    Ángela Rojas , Yolanda Sánchez-Torrijos , Antonio Gil-Gómez , Chang-Hai Liu , Clara Rodríguez-Rivas , María Teresa Ferrer , Manuel Romero-Gómez
    Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second cause of cancer related death due to latent liver disease, late diagnosis and non-available therapeutic treatment. Liver biopsy is still the gold standard in order to know the molecular biology of the tumor,... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:31. | doi:10.20517/2394-5079.2018.60
    Published on: 6 Jul 2018  | Viewed:82  | Downloaded:14
    +HTML| PDF
  • Review|Open Access

    Oncogenic Wnt3a: a promising specific biomarker in hepatocellular carcinoma

    Min Yao , Miao Fang , Wen-Jie Zheng , Deng-Fu Yao
    Hepatocellular carcinoma (HCC) is still one of the most common and rapidly fatal malignancies worldwide with a multi-factorial, multi-step, complex process, and poor prognosis. Early discovery and effective therapy of HCC are of utmost importance. Recent studies demonstrated that Wnt/β-catenin... Read more
    Hepatoma Res 2018;4:30. | doi:10.20517/2394-5079.2018.32
    Published on: 5 Jul 2018  | Viewed:110  | Downloaded:12
    +HTML| PDF
  • Review|Open Access

    Understanding the inflammation-cancer transformation in the development of primary liver cancer

    Hong-Jin Chen , Ming-Hua Hu , Fang-Gui Xu , Hao-Jun Xu , Jun-Jun She , Hong-Ping Xia
    Primary liver cancer is one of the leading causes of cancer-related deaths worldwide. China has more than 55% liver cancer cases globally. The development of hepatocellular carcinoma (HCC) was caused by a variety of risks factors, including chronic inflammation by virus, alcohol consumption and... Read more
    Hepatoma Res 2018;4:29. | doi:10.20517/2394-5079.2018.18
    Published on: 5 Jul 2018  | Viewed:271  | Downloaded:23
    +HTML| PDF
  • Review|Open Access

    Pro-oncogenic role of SerpinB3 in hepatocellular carcinoma

    Andrea Martini , Patrizia Pontisso
    Hepatocellular carcinoma (HCC) is one of the most relevant sanitary problems for its prevalence and poor prognosis. This tumor is characterized by highly heterogeneous features, both at clinical and molecular level. SerpinB3 (squamous cell carcinoma antigen-1 or SCCA1) is a serine-protease... Read more
    This article belongs to the Special Issue New Insights in Liver Cancer
    Hepatoma Res 2018;4:28. | doi:10.20517/2394-5079.2018.50
    Published on: 29 Jun 2018  | Viewed:204  | Downloaded:24
    +HTML| PDF
  • Review|Open Access

    Hypoxic microenvironment and hepatocellular carcinoma treatment

    Ci-Ai Lin , Lin-Lin Chang , Hong Zhu , Qiao-Jun He , Bo Yang
    Hepatocellular carcinoma (HCC) is one of the most rapidly growing and prevalent cancers in the whole world. The characterized hypoxia region inside the HCC tumors has been recently found as the key driver of HCC malignance and treatment failure, leading to a variety of hypoxia-related biological... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:26. | doi:10.20517/2394-5079.2018.27
    Published on: 29 Jun 2018  | Viewed:167  | Downloaded:14
    +HTML| PDF
  • Original Article|Open Access

    Expression quantitative trait loci for PVT1 contributes to the prognosis of hepatocellular carcinoma

    Ting Tian , Ci Song , Zhe-Ning Pu , Zi-Jun Ge , Cheng-Xiao Yu , Ji-Bin Liu , Zhi-Bin Hu
    Aim: Plasmacytoma variant translocation 1 (PVT1), a long intergenic non-coding RNA, was overexpressed in liver cancer. A single nucleotide polymorphism (SNP) rs4733586 was identified as an expression quantitative trait loci (eQTL) for PVT1 using bioinformatics analysis. This study was to assess... Read more
    Hepatoma Res 2018;4:27. | doi:10.20517/2394-5079.2018.24
    Published on: 29 Jun 2018  | Viewed:159  | Downloaded:6
    +HTML| PDF
  • Review|Open Access

    HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: still an issue?

    Francesco Paolo Russo , Martina Tessari , Angela Imondi , Erica Nicola Lynch , Fabio Farinati
    New regimens with direct-acting antivirals (DAAs) agents have changed both efficacy and safety of hepatitis C virus (HCV)-treatment, as almost all patients can be treated and cured at any stage of liver disease. The rates of sustained virological response to currently available combinations... Read more
    This article belongs to the Special Issue New Insights in Liver Cancer
    Hepatoma Res 2018;4:25. | doi:10.20517/2394-5079.2018.52
    Published on: 27 Jun 2018  | Viewed:363  | Downloaded:36
    +HTML| PDF
  • Review|Open Access

    Epidemiology and viral risk factors for hepatocellular carcinoma in the Eastern Mediterranean countries

    Suna Yapali , Nurdan Tozun
    Given the high prevalence of viral hepatitis in the Eastern Mediterranean countries, hepatitis B and C infections are the major causes of hepatocellular carcinoma (HCC) in the region. Most cases are associated with cirrhosis related to hepatitis B or C infection. Environmental, host genetic and... Read more
    This article belongs to the Special Issue What More We can do on Hepatitis C?
    Hepatoma Res 2018;4:24. | doi:10.20517/2394-5079.2018.57
    Published on: 27 Jun 2018  | Viewed:197  | Downloaded:10
    +HTML| PDF
  • Review|Open Access

    Molecular targeting of antiviral drugs used against hepatitis C virus infection

    Mohammad Irshad , Priyanka Gupta , Khushboo Irshad
    Present study reports an update on the molecular interaction of antiviral drugs with viral and host cell components during hepatitis C virus (HCV) infection. In addition to the traditional therapeutic drug regimen, termed as standard of care, some recent drugs have been added in the existing... Read more
    This article belongs to the Special Issue What More We can do on Hepatitis C?
    Hepatoma Res 2018;4:23. | doi:10.20517/2394-5079.2018.25
    Published on: 26 Jun 2018  | Viewed:191  | Downloaded:11
    +HTML| PDF
  • Review|Open Access

    Time for hepatocellular carcinoma immunotherapy: insights for successful clinical applications in this challenging tumor

    Gabriele Missale , Elisabetta Cariani
    The multiplicity and phenotype of intratumoral immune infiltrate have been shown to influence the clinical outcome of hepatocellular carcinoma (HCC), thus providing a strong rationale to therapeutic interventions aimed at restoring the dysfunctional immune response against the tumor. Improving... Read more
    This article belongs to the Special Issue New Insights in Liver Cancer
    Hepatoma Res 2018;4:22. | doi:10.20517/2394-5079.2018.72
    Published on: 25 Jun 2018  | Viewed:376  | Downloaded:34
    +HTML| PDF
  • Review|Open Access

    Pathway analysis provides insight into the genetic susceptibility to hepatocellular carcinoma and insight into immuno-therapy treatment response

    Yih-Kuang Lu , Jacob Morris Brill , Ardesher Aghili , Kenneth Howard Buetow
    Clear evidence exists for genetic susceptibility to hepatocellular carcinoma (HCC). Genome-wide association studies have identified multiple candidate susceptibility loci. These loci suggest that genetic variation in the immune system may underpin HCC susceptibility. Genes for the antigen... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:21. | doi:10.20517/2394-5079.2018.44
    Published on: 22 Jun 2018  | Viewed:411  | Downloaded:22
    +HTML| PDF
  • Review|Open Access

    Intrahepatic cholangiocarcinoma: review and update

    Vincenzo Cardinale , Maria Consiglia Bragazzi , Guido Carpino , Sabina Di Matteo , Diletta Overi , Lorenzo Nevi , Eugenio Gaudio , Domenico Alvaro
    Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies that could develop at any level from the biliary tree. CCA is currently classified into intrahepatic (iCCA), perihilar and distal on the basis of its anatomical location. Of note, these three CCA subtypes have common features but... Read more
    This article belongs to the Special Issue New Insights in Liver Cancer
    Hepatoma Res 2018;4:20. | doi:10.20517/2394-5079.2018.46
    Published on: 19 Jun 2018  | Viewed:571  | Downloaded:66
    +HTML| PDF
  • Review|Open Access

    Mitoepigenetics and hepatocellular carcinoma

    María Guadalupe Lozano-Rosas , Enrique Chávez , Alejandro Rusbel Aparicio-Cadena , Gabriela Velasco-Loyden , Victoria Chagoya de Sánchez
    Mitochondria are the center of energy production in eukaryotic cells and are crucial for several cellular processes. Dysfunctional mitochondria have been associated with cancer progression. Mitochondria contain their own circular DNA (mtDNA), which codes for 13 proteins, 2rRNA, 22tRNA and... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:19. | doi:10.20517/2394-5079.2018.48
    Published on: 19 Jun 2018  | Viewed:389  | Downloaded:38
    +HTML| PDF
  • Review|Open Access

    Ablative techniques in hepatocellular carcinoma treatment

    Ehsun Naeem , Shahab Abid
    Hepatocellular carcinoma has been known to arise commonly in the setting of chronic liver disease. Due to its association with cirrhosis, patients with hepatocellular carcinoma often present with markedly diminished hepatic functional reserve, making them poor surgical candidates. For such... Read more
    This article belongs to the Special Issue What More We can do on Hepatitis C?
    Hepatoma Res 2018;4:18. | doi:10.20517/2394-5079.2018.22
    Published on: 13 Jun 2018  | Viewed:328  | Downloaded:29
    +HTML| PDF
  • Review|Open Access

    Pre-S2 and HBV associated hepatocellular carcinoma

    Ying Zheng , Yan-Yan Qian , Hong Fan
    Hepatitis B virus (HBV) infection is a primary cause of hepatocellular carcinoma (HCC). Under selection pressures of host immunity and/or immunoprophylaxis and antiviral therapies, HBV evolves by accumulating mutations in its genome. Several studies highlighted the considerable importance of HBV... Read more
    Hepatoma Res 2018;4:17. | doi:10.20517/2394-5079.2018.08
    Published on: 31 May 2018  | Viewed:352  | Downloaded:31
    +HTML| PDF
  • Review|Open Access

    T cell immunotherapy in hepatitis B virus related hepatocellular carcinoma

    Morteza Hafezi , Antonio Bertoletti , Anthony T. Tan
    Chronic hepatitis B Virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC). While multiple treatment modalities are available, liver transplantation remains the sole curative treatment for advanced stages of HCC, and hence new treatment approaches are required to fulfill... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:16. | doi:10.20517/2394-5079.2018.55
    Published on: 30 May 2018  | Viewed:793  | Downloaded:46
    +HTML| PDF
  • Original Article|Open Access

    Hepatocellular carcinoma in patients without cirrhosis: relevance and clinical characteristics

    Kellyane Santana Dias Carvalho , Luciano E. Fonseca , Helma P. Cotrim
    Aim: The present study evaluated the frequency of hepatocellular carcinoma (HCC) in patients without cirrhosis. Methods: HCC patients were recruited from two reference centers for liver disease in Northeast Brazil from 2010 to 2016. The diagnosis of HCC and cirrhosis was based on international... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:15. | doi:10.20517/2394-5079.2018.13
    Published on: 29 May 2018  | Viewed:405  | Downloaded:39
    +HTML| PDF
  • Review|Open Access

    New strategy to distinguish clonal origin of RHCC/MHCC between intrahepatic metastasis and multicentric occurrence

    Han Wang , Wen-Ming Cong
    Hepatocellular carcinoma (HCC) is a kind of malignancy with high potential of metastasis and multicentric occurrence. The treatment of recurrent hepatocellular carcinoma (RHCC) and multinodular hepatocellular carcinoma (MHCC) is always a nodus because of the diverse clonal origin of RHCC/MHCC.... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:14. | doi:10.20517/2394-5079.2018.16
    Published on: 28 May 2018  | Viewed:664  | Downloaded:52
    +HTML| PDF
  • Original Article|Open Access

    Neoadjuvant hepatic arterial infusion chemotherapy for resectable hepatocellular carcinomas

    Rina Tsutsui , Hiroaki Nagamatsu , Osamu Itano , Akihiro Deguchi , Tsubasa Tsutsumi , Mamoru Hiraki , Naohisa Mizukami , Jun Akiba
    Aim: To evaluate the effect of neoadjuvant hepatic arterial infusion chemotherapy (HAIC) on the survival of patients with resectable hepatocellular carcinoma (HCC). Methods: Between January 2003 and January 2014, 80 patients underwent hepatic resection for HCC. Of these patients, we evaluated 49... Read more
    Hepatoma Res 2018;4:13. | doi:10.20517/2394-5079.2018.20
    Published on: 11 May 2018  | Viewed:1108  | Downloaded:50
    +HTML| PDF
  • Original Article|Open Access

    Beta2-glycoprotein I cooperate with hepatitis B surface antigen promotes hepatocellular carcinogenesis via the nuclear factor kappa B signal pathway were enhanced by the lipopolysaccharide

    Xue-Li Ding , Xue Jing , Nai-Jun Han , Zi-Bin Tian , Pu-Jun Gao , Lin Yang , Ya-Nan Yu
    Aim: We aimed to elucidate whether beta2-glycoprotein I (β2GPI) cooperation with hepatitis B surface antigen (HBsAg) promoted hepatocellular carcinogenesis enhanced by the lipopolysaccharide (LPS) via activation of nuclear factor kappa B (NF-κB) and expression of tumor necrosis factor-α (TNF-α),... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:12. | doi:10.20517/2394-5079.2018.07
    Published on: 28 Apr 2018  | Viewed:470  | Downloaded:37
    +HTML| PDF
  • Review|Open Access

    Systemic therapies for hepatocellular carcinoma: a recap of the current status

    Petros Giovanis , Manuela De Bona , Fabio Farinati , Andrea Buda , Riccardo Berletti , Fable Zustovich , Simona D’Ippolito , Michele De Boni , Umberto Cillo , Davide Pastorelli
    After decades of frustrating nihilism due to lack of innovative therapeutic solutions, the onco-hepatological community is facing up to important novelties for the treatment of intermediate and advanced stages of liver cancer. Four new drugs have been investigated and resulted in positive data:... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:10. | doi:10.20517/2394-5079.2018.21
    Published on: 27 Apr 2018  | Viewed:1048  | Downloaded:103
    +HTML| PDF
  • Original Article|Open Access

    A potential clinical based score in hepatitis C virus cirrhotic patients to exclude small hepatocellular carcinoma

    Denise Cerqueira Paranaguá-Vezozzo , Celso Eduardo Lourenço Matielo , Daniel Ferraz de Campos Mazo , Lucas Souto Nacif , Mario Guimaraes Pessoa , Gleicy Luz Reinoso Pereira , Roque Gabriel Rezende de Lima , Patricia Momoyo Yoshimura Zitelli , Suzane Kioko Ono , Flair José Carrilho
    Aim: Hepatitis C virus (HCV) cirrhosis is an important cause of hepatocellular carcinoma (HCC). This study aimed to identify factors of HCC presence among HCV cirrhotic patients with and without small diameter HCC (≤ 3 cm). Methods: A case control transversal study between 1998 and 2003 including... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:11. | doi:10.20517/2394-5079.2018.17
    Published on: 27 Apr 2018  | Viewed:743  | Downloaded:59
    +HTML| PDF
  • Original Article|Open Access

    Lycopene treatment stalls the onset of experimentally induced hepatocellular carcinoma: a radioisotopic, physiological and biochemical analysis

    Nisha Bhatia , Baljinder Singh , Ashwani Koul
    Aim: The present study was aimed to determine the modulatory role of lycopene enriched tomato extract (LycT) during initiation of N-nitrosodiethylamine (NDEA) induced hepatocellular carcinoma (HCC). Methods: Female Balb/c mice were divided into 4 groups: control, NDEA (200 mg NDEA/kg b.wt,... Read more
    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:9. | doi:10.20517/2394-5079.2018.04
    Published on: 27 Mar 2018  | Viewed:881  | Downloaded:26
    +HTML| PDF
  • Original Article|Open Access

    Prediction of post-progression survival in patients with advanced hepatocellular carcinoma treated with sorafenib by using time-dependent changes in clinical characteristics

    Yoshiyuki Wada , Yuko Takami , Hajime Matsushima , Masaki Tateishi , Tomoki Ryu , Munehiro Yoshitomi , Hideki Saitsu
    Aim: Sorafenib has been shown to improve time to tumor progression (TTP) and overall survival (OS) in patients with hepatocellular carcinoma (HCC); however, post-progression survival (PPS) has not been well characterized in these patients. This study aimed to evaluate the predictors of PPS by... Read more
    Hepatoma Res 2018;4:8. | doi:10.20517/2394-5079.2017.39
    Published on: 6 Mar 2018  | Viewed:1299  | Downloaded:95
    +HTML| PDF
  • Case Report|Open Access

    Congenital absence of the portal vein complicated by hepatocellular carcinoma in the liver of an adult woman: review of imaging, literature and management

    Ankit Mehta , Shree R. Venkat , Lorraine Portelance , Lynn G. Feun
    We present a case of absence of the portal vein and Laennec’s cirrhosis in a 51-year-old female who was diagnosed with hepatocellular carcinoma (HCC). Only 101 cases of this malformation of the splanchnic vasculature have been reported of which 4 were reported to have HCC. Patient had disease... Read more
    This article belongs to the Special Issue Novel Approaches for HCC
    Hepatoma Res 2018;4:7. | doi:10.20517/2394-5079.2017.35
    Published on: 27 Feb 2018  | Viewed:1707  | Downloaded:72
    +HTML| PDF
  • Review|Open Access

    Direct antiviral therapy for hepatitis C and hepatocellular carcinoma: facing the conundrum

    Federica Buonfiglioli , Stefano Brillanti
    Direct antiviral therapy has dramatically changed our possibility to eradicate hepatitis C virus (HCV) infection in all stages of chronic liver disease, with sustained virological response rates well above 90%. HCV eradication should lead to a better prognosis even after cirrhosis has... Read more
    Hepatoma Res 2018;4:6. | doi:10.20517/2394-5079.2017.42
    Published on: 10 Feb 2018  | Viewed:2510  | Downloaded:174
    +HTML| PDF
  • Review|Open Access

    Treatment of high-burden hepatocellular carcinoma: an oncologist perspective

    Landon L. Chan , Stephen L. Chan
    Hepatocellular carcinoma (HCC) is recognized as a major global healthcare burden. Although there have been tremendous improvements in cancer screening and treatment, HCC mortality rate remains high. Many patients with HCC present late to medical attention and thus are not candidates for curative... Read more
    This article belongs to the Special Issue Management of Huge and Advanced Hepatocellular Carcinoma
    Hepatoma Res 2018;4:5. | doi:10.20517/2394-5079.2017.49
    Published on: 7 Feb 2018  | Viewed:2149  | Downloaded:114
    +HTML| PDF
  • Cohort Profile|Open Access

    Qidong hepatitis B virus infection cohort: a 25-year prospective study in high risk area of primary liver cancer

    Tao-Yang Chen , Geng-Sun Qian , Chun-Sun Fan , Yan Sun , Jin-Bing Wang , Pei-Xin Lu , Xue-Feng Xue , Yan Wu , Qi-Nan Zhang , Yan Jin , Yi-Qian Wu , Yu Gan , Jian-Quan Lu , Thomas W. Kensler , John D. Groopman , Hong Tu
    Qidong hepatitis B virus (HBV) infection cohort (QBC) is a prospective community-based study designed to investigate causative factors of primary liver cancer (PLC) in Qidong, China, where both PLC and HBV infection are highly endemic. Residents aged 20-65 years, living in seven townships of... Read more
    Hepatoma Res 2018;4:4. | doi:10.20517/2394-5079.2017.50
    Published on: 26 Jan 2018  | Viewed:2236  | Downloaded:98
    +HTML| PDF
  • Original Article|Open Access

    Hepatocellular carcinoma in the setting of interferon-free treatment for chronic HCV hepatitis - experience of a single center

    Elena Laura Iliescu , Adriana Mercan-Stanciu , Letitia Toma , Elena Simona Ioanitescu , Radu Dumitru , Daniel Rusie
    Aim: This study aims to analyze the particularities of hepatitis C induced hepatocellular carcinoma (HCC), developed during or after treatment with direct-acting antivirals. Methods: We conducted an observational prospective study on 278 patients, who underwent treatment for hepatitis C related... Read more
    Hepatoma Res 2018;4:3. | doi:10.20517/2394-5079.2017.48
    Published on: 18 Jan 2018  | Viewed:1964  | Downloaded:69
    +HTML| PDF
  • Original Article|Open Access

    Comparison of outcomes between laparoscopic vs. open liver resection for intermediate stage hepatocellular carcinoma

    Avril David , YoungRok Choi , Ho-Seong Han , Yoo-Seok Yoon , Jai Young Cho
    Aim: The Barcelona Clinic Liver Score (BCLC) currently limits hepatic resection only for small, solitary tumors measuring 2-3 cm with no signs of portal hypertension (PHT) or macrovascular invasion. The aim of this study was to show the benefit of surgical resection, and to compare the... Read more
    This article belongs to the Special Issue Management of Huge and Advanced Hepatocellular Carcinoma
    Hepatoma Res 2018;4:2. | doi:10.20517/2394-5079.2017.51
    Published on: 18 Jan 2018  | Viewed:1143  | Downloaded:73
    +HTML| PDF
  • Original Article|Open Access

    Clinical and molecular sub-classification of hepatocellular carcinoma relative to alpha-fetoprotein level in an Asia-Pacific island cohort

    Scott T. Nishioka , Miles M. Sato , Linda L. Wong , Maarit Tiirikainen , Sandi A. Kwee
    Aim: Increased serum alpha-fetoprotein (AFP) levels are associated with specific molecular sub-classes of hepatocellular carcinoma (HCC), supporting AFP as a predictive or therapeutic biomarker for precision treatment of this disease. Considering recent efforts to validate HCC molecular... Read more
    Hepatoma Res 2018;4:1. | doi:10.20517/2394-5079.2017.46
    Published on: 12 Jan 2018  | Viewed:2803  | Downloaded:123
    +HTML| PDF
Hepatoma Research ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.